The LIBRETTO-001 trial demonstrated the activity of the selective rearrangement during transfection (RET) inhibitor selpercatinib in advanced <i>RET</i> fusion-positive non-small cell lung cancer (NSCLC) and resulted in the drug's approval for this indication. The gene discussed is RET; the disease is non-small cell lung carcinoma.